Completed NA INTERVENTIONAL 1-arm NCT01363284

Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients

Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients Based on Assessment of Endogenous Analgesia Capabilities

Sponsor: Eli Lilly and Company

Conditions Diabetes Painful Neuropathy

Interventions Duloxetine

Updated 6 times since 2017 Last updated: Oct 10, 2017 Started: Jun 30, 2010 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Diabetes and Painful Neuropathy and is currently completed. Eli Lilly and Company leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Oct 2017 — Jun 2018 [monthly]

Completed NA

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — Oct 2017 [monthly]

Unknown Status NA

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Rambam Health Care Campus

Data source: Rambam Health Care Campus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Haifa, Israel